C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

CCCC Account Payables

Amounts the company owes suppliers for goods and services received.

C4 Therapeutics, Inc.NASDAQ: CCCC

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 13.2% from a year ago

Account payables stood at $773K at the end of Q1 FY2026, up 13.2% from a year earlier and down 9.9% from the prior quarter. Over 3 fiscal years it compounded at -9.9% a year.

Context

  • Account payables amounted to 0.2% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Account payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +13.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$773K-9.9% QoQ
Last fiscal yearDec 2025
$858K-35.4% YoY
Year agoMar 2025
$683K+13.2% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.2%——
1 year-35.4%——
3-year CAGR-9.9%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
858K USD
Year-over-year change
-35.4%
4-year CAGR
-33.9%

Account Payables vs competitors

How CCCC compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +13.2% is the 2nd highest of 9, against a peer median of -24.5%.
  • Account payables amounts to 0.2% of total assets for CCCC, versus a peer median of 1.9%.
CCCC Competitors
Account Payables for CCCC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SGMOSangamo Therapeutics, Inc.Mar 2026$19.31M USD+6.1%-13.6%32.2%
MISTMilestone Pharmaceuticals Inc.Mar 2026$10.02M USD+320.4%+35.6%5.2%
CDXSCodexis, Inc.Mar 2026$2.13M USD-64.8%-21.8%1.6%
MOLNMolecular Partners AGMar 2026CHF 1.92M CHF-19.9%-2.0%2.2%
OABIOmniAb, Inc.Mar 2026$1.65M USD-14.5%-14.2%0.6%
IMDXInsight Molecular Diagnostics Inc.Mar 2026$1.62M USD-29.1%+26.6%4.0%
CCCCC4 Therapeutics, Inc.Mar 2026$773K USD+13.2%-9.9%0.2%
ARMPArmata Pharmaceuticals, Inc.Mar 2026$660K USD-32.7%-46.6%0.9%
PEPGPepGen Inc.Mar 2026$622K USD-77.0%-15.5%0.4%
Peer median (excluding CCCC) —-24.5%-13.9%1.9%

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents76.12M29.75M126.59M55.5M74.6M
Short-term Investments233.16M246.4M127.09M189.41M173.93M
Net Receivables5.72M1.47M11.8M3.1M2.4M
Inventory0(60.96M)000
Other Current Assets070.89M5.71M9.76M7.17M
Total Current Assets325.69M287.56M271.19M257.77M258.11M
Property, Plant & Equipment (Net)35.05M77.52M71.09M63.38M45.28M
Goodwill00000
Intangible Assets00000
Long-term Investments142.2M60.96M28.01M22.36M48.56M
Tax Assets00000
Other Non-current Assets3.82M4.81M6.17M6.1M7.13M
Total Non-current Assets181.08M143.28M105.26M91.84M100.97M
Total Assets506.77M430.84M376.45M349.6M359.08M
Account Payables4.51M1.17M1.45M1.33M858K
Short-term Debt02.29M000
Tax Payables00000
Deferred Revenue31.8M16.62M15.47M18.71M12.49M
Other Current Liabilities5.5M3.11M9.39M9.3M10.06M
Total Current Liabilities51.25M44.55M42.77M45.18M33.03M
Long-term Debt10.77M9.2M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)24.37M16.9M21.81M28.46M15.84M
Other Non-current Liabilities00000
Total Non-current Liabilities65.91M97.06M87.57M88.44M69.46M
Total Liabilities117.16M141.61M130.34M133.62M102.49M
Common Stock5K5K6K7K9K
Retained Earnings(267.72M)(395.89M)(528.38M)(633.7M)(738.69M)
Accumulated OCI(775K)(4.14M)(127K)53K50K
Other Stockholders Equity00000
Minority Interest00000
Total Equity389.61M289.23M246.11M215.99M256.59M
Total Debt42.88M87.15M70.98M65.76M59.98M
Net Debt(33.25M)57.4M(55.61M)10.26M(14.62M)

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.